Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on April 1, 2025
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its …
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will …
Nitrase Therapeutics Presents Preclinical Data from Multiple Studies Demonstrating Its Antibody Prevents Pathological Spread of Parkinson’s Disease in an Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
GlobeNewswire
·
April 1, 2025
- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 - Elevated nSyn is Found in Patients with Parkinson’s Disease, …
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, …
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
April 1, 2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 …
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
GlobeNewswire
·
April 1, 2025
MIAMI, April 01, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in the Jones Las Vegas …
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
·
April 1, 2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have …
BigCommerce Becomes NAED Corporate Partner to Advance Digital Innovation in Electrical Distribution, a Key B2B Market
GlobeNewswire
·
April 1, 2025
AUSTIN, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands and retailers, today announced its corporate partnership with the National Association of …
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
GlobeNewswire
·
April 1, 2025
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading …
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a …
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
GlobeNewswire
·
April 1, 2025
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK …
Study Finds Brain Training Also Helps Caregivers of Dementia Patients
GlobeNewswire
·
April 1, 2025
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- While a particular brain training app —BrainHQ from Posit Science — has already been shown to prevent cognitive decline and improve brain health in older adults, researchers at the University of Rochester …
Evaxion announces business update and full year 2024 financial results
GlobeNewswire
·
April 1, 2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results. …
Context Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 1, 2025
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its …
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
GlobeNewswire
·
April 1, 2025
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, …
Kura Oncology to Participate in Stifel Targeted Oncology Forum
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the …
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
GlobeNewswire
·
April 1, 2025
PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 …
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule …
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, …
LeddarTech apporte d’autres modifications à sa facilité de crédit et à son offre de financement relais et annonce la réception d’un avis d’insuffisance du NASDAQ
GlobeNewswire
·
April 1, 2025
QUÉBEC, Canada, 01 avr. 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (« LeddarTech ») (NASDAQ : LDTC), une société de logiciels automobiles qui fournit des technologies logicielles de fusion bas niveau de capteurs et de perception alimentées par l’IA …